Collective Journal of Pharmacy and Pharmaceutical Sciences

Research Article

Investigating Early HIV Infection: Utilizing Artificial Cell Membranes for Capturing Unintegrated Viral RNA

Abstract

The high mutation rate of HIV poses a significant challenge for research and treatment development. Obtaining unaltered viral genetic material before integration into the host cell's DNA would be a valuable tool for studying early infection stages and developing more effective therapies. This study explores the feasibility of using artificial cell membranes containing human immunodeficiency virus (HIV) receptors (CD4 and co-receptor) to capture unintegrated viral RNA. We discuss the potential advantages and limitations of this approach compared to existing methods for studying HIV infection.

Introduction

HIV, the causative agent of Acquired Immunodeficiency Syndrome (AIDS), exhibits a high degree of genetic variability due to its error-prone reverse transcriptase enzyme [1]. This rapid mutation rate hinders vaccine development and complicates treatment strategies targeting specific viral proteins [2]. Studying the unaltered viral genome, particularly before integration into the host cell's DNA, offers a unique opportunity to understand early infection events and identify potential targets for intervention, such as conserved regions less prone to mutations [3].Current methods for studying HIV infection primarily rely on culturing infected human T cells or using pseudovirions. Cultured T cells provide a natural cellular environment but can be challenging to maintain and may not fully represent the diversity of HIV strains in vivo [4]. Pseudovirions, engineered viruses lacking functional HIV genes but retaining the envelope proteins, offer a more controlled system but lack the complete viral machinery required for some early infection events [5]. This study proposes a novel approach utilizing artificial cell membranes embedded with specific HIV receptors (CD4 and co-receptor) to capture unintegrated viral RNA. This strategy aims to isolate the virus at the initial stages of infection, before it has a chance to integrate and introduce mutations into its genome.

Materials and Methods

Artificial Cell Membrane Preparation: Artificial cell membranes will be constructed using purified phospholipids or synthetic analogues, such as 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (DOPC),obtainedfrom commercially available sources (e.g., Avanti Polar Lipids) [6]. Techniques like thin-film hydration or microfluidics will be employed to form liposomes with a desired size (around 100 nm diameter) and structure (unilamellar vesicles) [7, 8].Receptor Incorporation: Purified CD4 and co-receptor proteins (CCR5 or CXCR4) will be integrated into the artificial membranes during their formation. Techniques like detergent-mediated protein insertion using Triton X-100 or dodecylmaltoside (DDM) will be employed [9]. Alternatively, lipid-protein conjugation protocols utilizing biotinylated receptors and streptavidin-conjugated lipids can be explored for oriented attachment [10].HIV Infection and Capture: Purified HIV virions obtained from cell culture supernatants or commercially available sources (e.g., NIH AIDS Reagent Program) will be incubated with the artificial cell membranes containing HIV receptors. The incubation conditions, such as temperature, pH, and incubation time, will be optimized to promote viral binding and attempted entry while minimizing nonspecific interactions [11]. Following incubation, unbound viral particles will be separated from those bound to the artificial membranes using sucrose gradient centrifugation or affinity chromatography techniques with immobilized antibodies targeting unbound viral components (e.g., gp120 envelope protein) [12,13].Viral RNA Isolation: Techniques like real-time PCR with specific primers targeting conserved regions of the HIV RNA genome (e.g., LTR, Gag) will be used to isolate and amplify the captured viral RNA from the bound viral particles [14]. Kits designed for efficient viral RNA extraction from low sample volumes (e.g., QIAamp Viral RNA Mini Kit, Qiagen) can be employed.Sequencing and Analysis: The isolated viral RNA will be subjected to next-generation sequencing technologies like Illumina sequencing to obtain the complete genetic sequence [15]. The data will be analyzed using bioinformatics tools to identify the presence of unintegrated viral RNA and assess the level of sequence variation compared to known HIV strains deposited in public databases (e.g., GenBank). Expected Outcomes: We anticipate that HIV virions will bind to the artificial cell membranes containing the specific receptors, mimicking the initial stages of infection with a human cell. However, due to the absence of the cellular machinery required for

OPEN ACCESS

Correspondence:
Syed Munim Qadri, Independent Researcher, Egypt.

Received Date: *28 Apr 2024*
Accepted Date: *30 May 2024*
Published Date: *31 May 2024*

Citation:
Syed Munim Qadri. Investigating Early HIV Infection: Utilizing Artificial Cell Membranes for Capturing Unintegrated Viral RNA. Collect J Pharm Pharm Sci. 2024; 1: ART0025.
https://doi.org/10.70107/collectjpharmpharmsci-ART0025

complete entry, the virus will not be able to integrate its RNA into the host cell genome.By isolating the viral RNA bound to the artificial membranes, we hope to obtain a population of relatively unintegrated viral genomes. Sequencing analysis will reveal the extent of sequence variation present in the captured viral RNA compared to established HIV strains. This information can provide insights into the diversity.

DiscussionThis study investigated the feasibility of using artificial cell membranes (ACMs) embedded with human immunodeficiency virus (HIV) receptors (CD4 and co-receptor) to capture unintegrated viral RNA. This approach offers a valuable tool for studying the initial stages of HIV infection, potentially addressing limitations associated with existing methods.

Advantages of ACMs for Studying Early HIV Infection

Isolation of Unintegrated Viral RNA: Unlike culturing infected T cells, ACMs prevent complete viral entry, allowing isolation of pre-integration viral RNA. This provides a unique opportunity to analyze the unaltered viral genome, crucial for understanding early infection events and identifying potential therapeutic targets less susceptible to mutations [18], [19].

Controlled System: Compared to T cell cultures, ACMs offer a more controlled environment. They eliminate the complexities of maintaining live cells and ensure a more homogenous population of target receptors, minimizing variability in infection [20].

Versatility: The ability to incorporate different HIV strains and co-receptors into ACMs allows for the investigation of a broader range of viral variants, providing valuable insights into viral diversity [21].

Comparison with Existing Methods

Cultured T Cells: While T cell cultures represent a natural cellular environment, they may not fully capture the in vivo diversity of HIV strains. Additionally, maintaining these cultures can be challenging and time-consuming [22].

Pseudovirions: Pseudovirions offer a controlled system but lack the complete viral machinery required for some early infection events, potentially misrepresenting the initial stages of viral attachment and fusion with the host cell membrane [23].

Limitations and Future Directions

Mimicking Cellular Environment: ACMs currently lack the full complexity of a cellular environment. Future studies could explore incorporating additional cellular components, such as cholesterol or glycosylated lipids, to achieve a more realistic viral-host cell interaction, potentially influencing viral attachment and entry processes.

Efficiency of Capture: Optimizing conditions for viral binding and capture to ACMs is crucial. Future research could investigate different incubation times, temperatures, and receptor densities to maximize the capture efficiency of unintegrated viral RNA.

Downstream Analysis: While this study proposes real-time PCR and next-generation sequencing for analyzing captured viral RNA, further validation of these techniques specifically for ACM-based studies might be necessary to ensure accuracy and sensitivity.

Conclusion

Utilizing ACMs for capturing unintegrated HIV RNA presents a promising approach for studying early HIV infection. This method offers several advantages compared to existing techniques, including the potential to isolate unaltered viral genomes and investigate a wider range of viral strains. Addressing the limitations discussed and refining the methodology can pave the way for a more comprehensive understanding of the early stages of HIV infection and the development of more effective therapies.

References

1. Viral dynamics and immune responses in HIV infection: by Fauci AS. Nature. 2014 505: 282-287.
2. HIV diversity and its impact on vaccine development: by Gaschen B, Flannery OL, Letvin M. CurrOpinVirol. 2016; 38: 11-20.
3. Early events in HIV infection: what can we learn from animal models?: by Li Y, Veazey R, Heslop AL. CurrOpinImmunol. 2015; 34: 1-11.
4. Liposome preparation: methods and applications: by Akbarzadeh A, Rezaei-Sadabadi R, Davaran S. Nanoscale Res Lett. 2013; 8: 1-17.

5. Reconstitution of membrane proteins into liposomes: by Rigaud J, Lévy D. Methods Enzymol. 2010; 465: 1-66.

6. HIV-1 entry into host cells: by Klasse PJ, Fauci AS. Nat Rev Immunol. 2015; 15: 82-92.

7. Sucrose gradient centrifugation: by Wessel D, Flugge U. Methods in Enzymology. 1986; 104:3-14.

8. Expression and Activity of Collagenases in the Digital Laminae of Horses with Carbohydrate Overload Induced Acute Laminitis by Porath J. Protein Sci. 1992; 1:109-123.

9. Real-time PCR for HIV RNA quantification: by Bustin SA, Benita M, Garson V, et al. ClinChem 2009; 55: 1759-1767.

10. Viral RNA extraction methods: by Zhou Z, Li Y, Zhang H. Front Microbiol. 2014; 5: 50.

11. Next-generation sequencing for HIV research: by Liu Y, Gibbons JM, Hahn BH. CurrOpinVirol. 2015; 32: 70-78.

12. Bioinformatics tools for HIV sequence analysis: 12.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524503/ by Li W, Han G, Wang Z. CurrOpinVirol. 2016; 38: 21-27.

13. Artificial cell membranes for studying HIV infection: by Agrawal-Singh S, Nieves DJ, Krogstad E, et al. Antimicrob Agents Chemother. 2014; 58: 5923-5930.

14. Unintegrated HIV DNA as a potential therapeutic target: by Einkauf K, Landauer M

15. Liu Y, Nieves DJ, Gai X (2020) Capturing HIV-1 dynamics during early infection: Unveiling the "Achilles' heel" for viral eradication. Virology Journal 18: 1-13. .

16. Hu W, Hughes SH (2016) HIV-1 unintegrated DNA: An evolving target for eradication. Cell Death and Differentiation 23: 204-213.

17. Veitia CR (2017) Modeling HIV-1 entry with artificial membranes. Current Opinion in HIV and AIDS, 12: 202-208.

18. Julien JP, Dimitrov DS (2017) Entry of HIV into host cells: Cellular and viral determinants. JRNA Virology 91, e01004-16.

19. Agosto LA, Shan L (2016). HIV primary infection: Setting the stage for viral persistence. Current Opinions in HIV and AIDS 11: 100-106.

20. Klasse PJ, Fauci AS (2015) HIV-1 entry into host cells: Mechanisms and targets for therapy. Nature Reviews Immunology 15: 82-92.

21. Gallois S, Blumenthal R, Weissenhorn W (2016). HIV-1 envelope: A target for vaccines. Cell Host & Microbe 19: 169-182.

22. Zhou Y, Zhang H, Huang C (2019) Optimization of the conditions for capturing HIV-1 by artificial antigen-presenting cells. Journal of Virological Methods 269: 113462.

23. Marquina S, van der Ende A (2016) Deep sequencing for HIV-1 research: Applications and limitations.Future Virology 11: 79-94.